Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From John Davis
A German case of PML in a patient treated with Ocrevus, but who was also previously treated with Tysabri, threatens to take the gloss off Roche’s new multiple sclerosis therapy.
The US rare diseases company Alexion appoints a new COO and is now looking for a new CFO, head of R&D, and head of human resources, as leadership changes leaves its CEO searching for a new executive team.
Protecting the function of mitochondria may be key to developing medicines to reduce the nerve damage caused by traumatic brain injuries. NeuroVive Pharmaceutical is moving its cyclosporine candidate into Phase IIb studies.
Recommendations on drugs awaiting approval from the European Medicines Agency's Committee for Medicinal Products for Human Use, and updates on the marketing authorization applications for individual products. Updated monthly.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Emerging Company Profile: The German company Cardior has been set up to evaluate inhibitors of a microRNA in the treatment of heart failure, a condition that is poorly treated by current therapies.